Cellply is a biotechnology company that develops scientific tools automating cell-based functional assays whose aim is to deeply characterize the mode of action of both approved and novel anti-cancer drugs, being able to evaluate the heterogeneity in function of both immune and tumor cells with a single-cell resolution.
CellPly’s technology automates therapy testing on both ex-vivo primary tumor samples, cell lines and immune cells to evaluate potency of a wide range of treatments, ranging from chemotherapies and molecularly-targeted treatments to antibody-based and cell-based immunotherapies.
CellPly solutions are developed to support both biopharma companies in the research and development of new therapies and clinicians by enabling next-generation predictive diagnostics.
